INTERMEDIATES
Afatinib Intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| (S)-N4-(3-chloro-4-fluorophenyl) -7-(tetrahydrofuran-3-yloxy) quinazoline-4,6-diamine |
314771-76-1 |  |
| trans-4-Dimethylaminocrotonic acid hydrochloride | 848133-35-7 |  |
| N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine | 162012-67-1 |  |
| Imatinib Intermediates | ||
| N-(2-Methyl-5-nitrophenyl)-4- (pyridin-3-yl)pyrimidin-2-amine | 152460-09-08 |  |
| N-(5-Amino-2-methylphenyl)-4-/-)3-pyridyl)-2-pyrimidineamine | 152460-10-1 |  |
| 4-(4-Methyl-piperaziro) Methyl Benzoic Acid | 106261-48-7 |  |
| Ibrutinib Intermediates | ||
| 5-Amino-3-(-4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile | 3300792-7-6 |  |
| Solifenacin Intermediates | ||
| (s)-1-phenyl-1,2,3,4-tetrahydro isoquinoline | 118864-75-8 |  |
| Pemetrexed Intermediates | ||
| 4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pymol[2,3-d] pyrirnodin-5yl) ethyl] benzoic acid | 137-281-39-1 |  |
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||
Gefitinib Intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| 7-methoxy-6-(3morpholin-4-ylpropoxy)quinazolin-4-(3h)-one | 199327-61-2 | |
| Methyl 5-hydroxy-4-methoxy-2- nitrobenzoate | 31839-20-0 | |
| (7-methoxy-4-oxo-1H- quinazolin-6-yl) acetate | 179688-53-0 | |
| Amiloride intermediates | ||
| 3-Aminopyrazine-2-carboxylic Acid | 5424-01-01 | |
| Olmesartan intermediates | ||
| 4-(1-Hydroxy-1-methylethyl)-2-propl-1H- imidazole-s -carboxlic acid ethyl ester | 144689-93-0 | |
| Dolutegravir Intermediates | ||
| Amino Acetaldehyde dimethyl acetal | 22483-09-6 | |
| Methyl-4-Methoxy Acetoacetate |
41051-15-4 | |
| Prazosin/ Terazosin/ Doxazosin/ Alfuzosin Intermediates | ||
| 4-Amino-2-chloro-6,7-dimethoxy Quinazoline |
23680-84-4 | |
| Fluconazole intermediates | ||
| 2(2,4 Diflurophenyl)-1-(4-amino)-1H-1,2,4-triazole-1-yl)-ethanone Hydrochloride |
|
|
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||
Fluconazole intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| 1-((2,4-Diflurophenyl)-1-(1H-1,2,4-triazole-1yl)_ethanone(DFTA) | 86404-63-9 | |
| 2-(2,4-Diflurophenyl)-1-
(1H-1,2,4-triazole-1yl)
2,3 Epoxy propane-Methane sulphonate (EPOXY MESYLATE) |
6386-77-8 | |
| Voriconazole Intermediates | ||
| 2_(1H-1,2,4 Triazol-1-yl)-2, 4-difluoro acetophenone |
86404-63-9 | |
| 6-(1-Bromo ethyl)-4-chloro-5- fluoro pyrimidine | 188416-28-6 | |
|
(2R,3s/2s, 3R)-3-(5-fluoropyrimidyin-4-yl-2-(2,4-difluorophenyl) -1-(1H-1,2,4 triazol-1-yl) butan-2-ol (racemic voriconazole) |
188416-29-7 | |
| (2R,3s)-2-(2,4-Difluorophenyl)-3-(5-fluoro Pyrimidine-4yl)-1 -(1H-1,2,4 triazol-1-yl) butan-2-ol camphor sulfonate |
137234-71-0 | |
| Efinaconazole Intermediates | ||
| 4-methylene piperidine | 148133-82-8 | |
|
1-(((2r,3S)-2-(2,4-difluorophenyl)-3-methloxiran- 2-yl)methyl)-1H-1,2,4-triazole |
188416-29-7 | |
| Terbinafine Intermediates | ||
| 6,6 Dimethylhept-1-en-4-yn-3-ol | 78629-20-6 | |
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||
Terbinafine Intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| Trans-1-Chloro-6,6-dimethylhept- 2-en-4-yne | 83554-69-2 | |
| N-(1-Naphthyl methyl)methyl
amine Hydrochloride |
65473-13-4 | |
| N-(1-Naphthyl methyl) methyl amine (Free Base) | 14489-75-9 | |
| (2E) N,6,6-Trimethyl-N-
(naphthalen-1-ylmethyl hept-2-en-4-yn-1-amine(Terbinafine Base) |
91161-71-6 | |
| Citalopram & Escitalopram Oxalate intermediates | ||
| 4-[(4-Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl- 3-(hydroxymethyl)- benzonitrile (Diol base) |
103146-25-0 | |
| 4-[(4-Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl] -3 hydroxy methyl benzonitrile Hydrochloride |
717133-25-0 | |
|
4-[(4-dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-1- butyl]-3 hydroxy methyl benzonitrile Hydrochloride |
103146-26-5 | |
| 4-[(4-Dimethylamino)0-1-(4-fluorophenyl)-1-hydroxybutyl] -3- (hydroxymethyl)-benzonitrile D-hemi tartaricacid salt |
128173-53-5 | |
| Lasartan Potassium Intermediates | ||
| 2-Butyl-4-chloro-1-[[(2'-(1 H-tetrazole-5-yl (1,1'-biphenyl)-4yl]methyl]-1H imidazole-5-methanol(losartan) |
114798-26-4 | |
| Dapoxetine Intermediates | ||
|
N,N-Dimethyl-1-phenyl-3-(1-napthalenyloxy) propanamine oxalic acid salt (Racemic Dapoxetine oxalate) |
|
|
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||
Dapoxetine Intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| (+)-N,N-Dimethyl-1-phenyl-3-
(1-napthalenyl oxy) propanamine (Dapoxetine free base) |
119356-77-3 | |
| Racemic Dapoxetine HCI | 1071929-03-7 | |
| Racemic Dapoxetine | 119356-76-2 | |
| S-Amlodipine Besylate Intermediates | ||
| S-Amlodipine Base | 103129-82-4 | |
| Zafirlukast Intermediates | ||
| 5- Nitro indole | 6146-52-7 | |
|
Methyl 4-(5-Amino-1-Methyl indol-3-yl Methyl)-3-Methoxy Benzoate |
107754-14-3 | |
| Sumatriptan Succinate Intermediates | ||
| 3-[2-Aminoethy]-N-methyl-1 H indole-5-methane sulfonamide (Suma stage 1) |
88919-22-6 | |
| 4-Hydrazino-N-methylbenzene methane sulfonamide HCI (HMBS) |
88933-16-8 | |
| 4-Chlorobutyraldehydesodiumbisulfite (ADDUCT) |
54322-20-2 | |
| 4-(N,N-Dimethylamino) butane diethyl acetal |
1116-77-4 | |
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||
Midazolam Intermediates
| Product Name | CAS No. | Structure |
|---|---|---|
| 8-chloro-6-(2-fluorophenyl)-1-methy- 4H-imidazol [1,5-a]benzodiazepine-3- Carboxylic acid |
59468-44-9 | |
| Rivastigmine Intermediates | ||
| (s)-[1-(3-hydoxypheny)ethyl)
Dimethylamine |
139306-10-8 | |
| 3-(1-(Dimethylamino) Ethyl]phenol |
105601-04-5 | |
| Rivaroxaban Intermediates | ||
| 4-(4-Aminophenyl)morpholin-3-one | 438056-69-0 | |
| (S)-(+)-N-(2,3-Epoxypropyl)phthalimide | 161596-47-0 | |
| Other Intermediates | ||
|
Diethyl 2-(2-(2,4-difluorophenyl) allyl)malonate |
159276-62-7 | |
| 2-(2-(2,4-difluorophenyl) propane-1,3-diol |
165115-73-1 | |
| 2-chloro-1-(2,4-difluorophenyl) ethan-1-one |
51336-94-8 | |
| Systematic Approach for Innovation | ||
| None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered or R&D purpose only. However the final responsibility lies exclusively with the buyer |
||